See more : The Eastern Company (EML) Income Statement Analysis – Financial Results
Complete financial analysis of Stayble Therapeutics AB (publ) (STABL.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Stayble Therapeutics AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- PlaySide Studios Limited (PLY.AX) Income Statement Analysis – Financial Results
- Sichuan Langsha Holding Ltd. (600137.SS) Income Statement Analysis – Financial Results
- LIDDS AB (publ) (LIDDS.ST) Income Statement Analysis – Financial Results
- e-therapeutics plc (ETXPF) Income Statement Analysis – Financial Results
- UTG, Inc. (UTGN) Income Statement Analysis – Financial Results
Stayble Therapeutics AB (publ) (STABL.ST)
About Stayble Therapeutics AB (publ)
Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 537.89 | 40.11K | 0.00 | 35.50K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.93M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 537.89 | 40.11K | 0.00 | -2.90M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | -8,164.23% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 9.14M | 13.68M | 6.07M | 4.82M | 2.43M | 2.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.00M | 24.95M | 9.14M | 13.68M | 6.07M | 4.82M | 2.43M | 2.40M |
| Other Expenses | -47.98K | 24.95M | 3.00M | 1.30M | 797.51K | 1.30M | 364.10K | -1.17M |
| Operating Expenses | 23.95M | 24.95M | 12.14M | 14.98M | 6.87M | 6.12M | 2.80M | 1.22M |
| Cost & Expenses | 23.95M | 24.95M | 12.14M | 14.98M | 6.87M | 6.12M | 2.80M | 1.22M |
| Interest Income | 217.00 | 33.61K | 29.02K | 396.17 | 1.52K | 0.00 | 0.00 | 700.00 |
| Interest Expense | 0.00 | 27.94K | 57.09K | 396.17K | 534.87K | 14.80K | 16.30K | 16.10K |
| Depreciation & Amortization | 24.00M | 24.95M | 12.14M | 14.98M | 6.87M | 6.12M | 2.80M | 891.23K |
| EBITDA | 309.41K | 0.00 | 0.00 | 0.00 | 0.00 | -2.68K | -2.18K | -1.19M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,277,813.14% | -15,256.79% | 0.00% | -3,345.63% |
| Operating Income | -23.95M | -24.80M | -12.14M | -14.93M | -6.87M | -6.12M | -2.80M | -1.19M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,278,096.10% | -15,256.79% | 0.00% | -3,347.32% |
| Total Other Income/Expenses | 217.28K | 270.51K | 49.52K | -562.34K | -533.35K | -14.80K | -16.40K | -312.57K |
| Income Before Tax | -23.74M | -24.53M | -12.09M | -15.49M | -7.41M | -6.13M | -2.81M | -1.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,377,252.61% | -15,293.69% | 0.00% | -3,390.99% |
| Income Tax Expense | 0.00 | -298.45K | -49.52K | 562.34K | 533.35K | -161.14K | -2.80M | -890.63K |
| Net Income | -23.74M | -24.23M | -12.04M | -16.05M | -7.94M | -6.13M | -2.81M | -1.20M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,476,409.13% | -15,293.69% | 0.00% | -3,390.99% |
| EPS | -0.92 | -1.70 | -0.85 | -1.80 | -0.63 | -0.69 | -0.32 | -0.14 |
| EPS Diluted | -0.92 | -1.70 | -0.85 | -1.80 | -0.63 | -0.69 | -0.32 | -0.14 |
| Weighted Avg Shares Out | 25.76M | 14.23M | 14.23M | 8.92M | 12.59M | 8.92M | 8.92M | 8.92M |
| Weighted Avg Shares Out (Dil) | 25.76M | 14.23M | 14.23M | 8.92M | 12.59M | 8.92M | 8.92M | 8.92M |
Source: https://incomestatements.info
Category: Stock Reports